In the Rat IgG treated groups, azelnidipine could significantly inhibit tumor growth as in Figure 6B, while the anti-tumor effect was abrogated with CD8+ T cells depleted (supplemental Figure S2c). The gene discussed is CD8A; the disease is neoplasm.